Unicycive Therapeutics, Inc. has announced its third-quarter financial results for 2026, revealing significant developments for the company and its future prospects. The company reported that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for oxylanthanum carbonate (OLC), with a target action date of March 25, 2027. This acceptance is a pivotal milestone for Unicycive as it aims to bring this much-needed treatment to patients suffering from kidney disease.
Shalabh Gupta, M.D., Chief Executive Officer of Unicycive, expressed optimism about the FDA's acceptance, stating, "We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients. With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch." This statement underscores the company's commitment to preparing for a successful market entry.
Background
Unicycive Therapeutics, Inc. is a biotechnology company focused on developing therapies for patients with kidney disease. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. Unicycive is publicly traded on the Nasdaq under the ticker symbol UNCY. The company has been actively filing various reports, including a recent 10-Q and an 8-K, indicating its ongoing operations and financial conditions.
What the Filing Says
According to the recent filing dated November 16, 2026, Unicycive disclosed that as of September 30, 2026, it had unaudited cash, cash equivalents, and marketable securities totaling $59 million. This financial position is expected to support the company’s operations and potential product launch beyond 2027. The press release accompanying the filing highlights the FDA's acceptance of the NDA for OLC, which was resubmitted following a Complete Response Letter (CRL) received in June 2026.
Impact
The acceptance of the NDA for OLC is expected to have a significant impact on Unicycive’s future, as it prepares for a potential launch. The company is also focusing on commercial readiness initiatives, including discussions with dialysis organizations and plans to hire a sales force if the drug is approved. The developments may influence competitors in the pharmaceutical preparations sector, as they may need to adjust their strategies in response to Unicycive's advancements.
What's Next
Looking ahead, Unicycive is preparing for the FDA's review process, with a focus on launch preparations in anticipation of a successful approval. The filing does not specify what happens next, but the company is likely to continue its efforts to engage with key stakeholders and enhance its commercial readiness.
Read Next
Cadiz Inc. reports Q3 results, shows $7.07 million loss
Ascentage Pharma's Drugs Included in China's Reimbursement List
IGI CEO to Present at Southwest IDEAS Investor Conference
FF EAI Robotics Ecosystem reports Q3 results amid challenges
Wetouch Technology Inc. Reports Q3 2026 Financial Results
AirJoule Technologies Reports Strong Q3 Results and Growth







